Gene Therapy for Osteosarcoma : "In Vitro" Characterization of Five Tumor Cell Lines and Development of Treatment Models "In Vivo"
Walling, Hobart W.
MetadataShow full item record
Four human osteosarcoma cell lines (MNNG, TE85, MG63, and G292) and a human-derived osteosarcoma metastatic to murine lung (MLM) were transduced "in vitro" using retroviral vectors containing the Herpes simplex thymidine kinase (HS-tk), human interleukin 2 (IL2). and B-galactosidase (BAG) genes. Each osteosarcoma cell line was stably transduced, and the HS-tk gene effectively conferred ganciclovir (GCV) susceptibility to transduced cells. Each cell line showed a bystander effect (whereby wild type tumor cells are killed by co-incubation with HS-tk positive tumor cells and GCV). MNNG cells were used to develop a series of experiments in athymic nude mice to investigate the utility of gene therapy for the treatment of experimental osteosarcomas. Subcutaneous implants of mixtures of tumor cells and HS-tk vector producer cells (vpc) resulted in the development of tumors which were completely cured upon administration of GCV. Subcutaneous implant of mixtures of transduced and wild-type cells resulted in a potent bystander effect upon administration of GCV, with complete tumor ablation when as little as ten percent of the cells were HS-tk positive. A significant anti-tumor response was seen against primary tumors comprised of unmodified cells when a secondary tumor of transduced cells was induced at a distance of one centimeter, which supports a soluble bystander factor model. The presence of IL2-transduced cells significantly improved the efficacy of treatment, suggesting a synergy between the HS-tk and IL2 gene products. A significant anti-tumor response was seen in the treatment of established osteosarcomas by the injection of HS-tk vpc.
135 leaves. Advisor: Dean A. Hoganson